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Abstract
Stress echocardiography is an established technique for the assessment of extent and severity of coronary artery
disease. The combination of echocardiography with a physical, pharmacological or electrical stress allows to detect
myocardial ischemia with an excellent accuracy. A transient worsening of regional function during stress is the
hallmark of inducible ischemia. Stress echocardiography provides similar diagnostic and prognostic accuracy as
radionuclide stress perfusion imaging or magnetic resonance, but at a substantially lower cost, without
environmental impact, and with no biohazards for the patient and the physician.
The evidence on its clinical impact has been collected over 35 years, based on solid experimental,
pathophysiological, technological and clinical foundations. There is the need to implement the combination of wall
motion and coronary flow reserve, assessed in the left anterior descending artery, into a single test. The
improvement of technology and in imaging quality will make this approach more and more feasible. The future
issues in stress echo will be the possibility of obtaining quantitative information translating the current qualitative
assessment of regional wall motion into a number. The next challenge for stress echocardiography is to overcome
its main weaknesses: dependance on operator expertise, the lack of outcome data (a widesperad problem in clinical
imaging) to document the improvement of patient outcomes. This paper summarizes the main indications for the
clinical applications of stress echocardiography to ischemic heart disease.
Background
Pathophysiologic mechanisms
Stress echocardiography is the combination of 2D echo-
cardiography with a physical, pharmacological, or elec-
trical stress [1]. The diagnostic endpoint for the
detection of myocardial ischaemia is the induction of a
transient change in regional function during stress. A
transient regional imbalance between oxygen demand
and supply usually results in myocardial ischaemia, the
signs and symptoms of which can be used as a diagnos-
tic tool [1]. Myocardial ischaemia results in a typical
‘cascade’ of events in which the various markers are hier-
archically ranked in a well-defined time sequence [2].
Flow heterogeneity, especially between the subendocar-
dial and subepicardial perfusion, is the forerunner of is-
chaemia, followed by metabolic changes, alteration in
regional mechanical function, and only at a later stage
by electrocardiographic changes, and pain. The
pathophysiological concept of the ischaemic cascade is
translated clinically into a gradient of sensitivity of dif-
ferent available clinical markers of ischaemia, with chest
pain being the least and regional malperfusion the most
sensitive. The reduction of coronary flow reserve (CFR)
is the common pathophysiological mechanism. Regard-
less of the stress used and the morphological substrate,
ischaemia tends to propagate centrifugally with respect
to the ventricular cavity: [3, 4] it involves primarily the
subendocardial layer, whereas the subepicardial layer is
affected only at a later stage if the ischaemia persists [4].
In fact, extravascular pressure is higher in the subendo-
cardial than in the subepicardial layer; this provokes a
higher metabolic demand (wall tension being among the
main determinants of myocardial oxygen consumption)
and an increased resistance to flow. In the absence of cor-
onary artery disease (CAD), CFR can be reduced in micro-
vascular disease (e.g. in syndrome X) or left ventricular
(LV) hypertrophy (e.g. arterial hypertension). In this con-
dition, angina with ST-segment depression can occur with
regional perfusion changes, typically in the absence of any
regional wall motion abnormalities during stress. Wall
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motion abnormalities are more specific than CFR and/or
perfusion changes for the diagnosis of CAD [5–10].
Diagnostic criteria
All stress echocardiographic diagnoses can be summa-
rized into four equations centered on regional wall func-
tion and describing the fundamental response patterns:
normal, ischemic, necrotic, and viable.
Normal response
A segment is normokinetic at rest and normal or hyper-
kinetic during stress.
Ischemic response
The function of a segment worsens during stress from
normokinesia to hypokinesia (decrease of endocardial
movement and systolic thickening), akinesia (absence of
endocardial movement and systolic thickening), or dys-
kinesia (paradoxical outward movement and possible
systolic thinning). However, a resting akinesia becom-
ing dyskinesia during stress reflects purely passive
phenomenon of increased intraventricular pressure
developed by normally contracting walls and should
not be considered a true active ischemia [1].
Necrotic response
A segment with resting dysfunction remains fixed during
stress.
Viability response
A segment with resting dysfunction may show either a
sustained improvement during stress indicating a non-
jeopardized myocardium (stunned) or improve during
early stress with subsequent deterioration at peak (bi-
phasic response). The biphasic response is suggestive of
viability and ischemia, with jeopardized myocardium fed
by a critically coronary stenosis [1] Table 1.
Ischaemic stressors
Exercise, dobutamine, and dipyridamole are the most
frequently used stressors for echocardiographic test [11].
There are distinct advantages and disadvantages to exer-
cise versus pharmacological stress. In Table 2 the stress
echo protocols are reported.
Exercise
Exercise echocardiography can be performed using ei-
ther a treadmill or bicycle protocol. When a treadmill
test is performed, post-exercise imaging is evaluated. Re-
gional wall motion abnormalities would persist long
enough into recovery to be detected but when recovery
is rapid false-negative results occur [11]. Some Authors
[12], perform peak-exercise imaging also during treadmill
by keeping the patient standing still. Although challenging
such an approach avoid false negative results in case of a
rapid recovery to resting conditions. Information on exer-
cise capacity, heart rate response, and rhythm and blood
pressure changes are analysed and, together with wall mo-
tion analysis, become part of the final interpretation [11].
Bicycle exercise echocardiography is performed during ei-
ther an upright or a recumbent posture. Unlike treadmill
test, bicycle exercise allows to obtain images during the
various levels of exercise. The supine position is the most
suited for exercise echocardiography due to its ease of
image acquisition in all views through the steps of the
graded exercise [13]. In the upright posture, imaging is
generally limited to apical views.
Dobutamine
The standard dobutamine stress protocol consists of
continuous intravenous infusion of dobutamine in 3 min
increments, starting with 5 μg/kg/min and increasing to
10, 20, 30, and 40 μg/kg/min. If no endpoint is reached,
atropine (up to 1 mg) is added to the 40 μg/kg/min do-
butamine infusion [11, 14, 15].
Dipyridamole
The standard dipyridamole protocol consists of an intra-
venous infusion of 0.84 mg/kg over 10 min, in two separ-
ate infusions: 0.56 mg/kg over 4 min, followed by 4 min of
no dose and, if still negative, and additional 0.28 mg/kg
over 2 min [11, 16, 17]. If no endpoint is reached, atropine
(up to 1 mg) is added [18]. The same overall dose of
0.84 mg/kg can be given over 6 min [11, 19]. Aminophyl-
line should be available for immediate use in case an
Table 1 Stress echocardiography in 4 equations
Rest + Stress = Diagnosis
Normokinesis + Normo-Hyperkinesis = Normal
Normokinesis + Hypo, A, Dyskinesis = Ischaemia
Akinesis + Hypo, Normokinesis = Viable
A-, Dyskinesis + A-, Dyskinesis = Necrosis




25 W x 2’ with incremental
loading
Dobutamine Infusion Pump 5 mcg/Kg/min 10-20-30-40 +
atropine (0.25 x 4) up to 1 mg
Dipyridamole Syringe 0.84 mg/Kg in 6’ or 0.84 mg/Kg
in 10’ + atropine (0.25 x 4) up
to 1 mg
Adenosine Syringe 140 mcg/Kg/min in 6’
Pacing External Pacing From 100 bpm with increments
of 10 beats/min up to target
heart rate
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adverse dipyridamole-related event occurs and rou-
tinely infused at the end of the test independent of
the result [1, 11].
Adenosine
Adenosine is usually infused at a maximum dose of
140 μg/kg/min over 6 min [3, 20]. When side-effects are
intolerable, down-titration of the dose is also possible.
Pacing
The presence of a permanent pacemaker can be exploited
to conduct a pacing stress test in a totally non-invasive
manner by externally programming the pacemaker to in-
creasing frequencies. Pacing is started at 100 bpm and in-
creased every 2 min by 10 bpm until the target heart rate
or other standard endpoints are achieved [3, 21]. A limit-
ing factor is, however, that several pacemakers cannot be
programmed to the target heart rate.
Indications to stress echo
Indications for stress echocardiography can be grouped
in very broad categories which can encompass the ma-
jority of patients (see Table 3) [11]:
(i) CAD diagnosis;
(ii)prognosis and risk stratification in patients with
established diagnosis (e.g. after myocardial
infarction);
(iii)preoperative risk assessment;




As a rule, the less informative the exercise ECG test is,
the stricter the indication for stress echocardiography
will be. Out of five patients, one is unable to exercise,
one exercises submaximally, and one exercises max-
imally but the ECG is uninterpretable.
The three main specific indications for pharmacologic
stress echocardiography can be summarized as follows:
(i) patients in whom the exercise stress test is
contraindicated (e.g. patients with severe arterial
hypertension);
(ii)patients in whom the exercise stress test is not
feasible (e.g. those with intermittent claudication);
(iii)patients in whom the exercise stress test was
nondiagnostic or yielded ambiguous results: inability
to achieve the target heart rate response, presence of
chest pain in the absence of significant
electrocardiographic changes, and a concomitance of
conditions lowering the reliability of the ECG
marker of ischemia (female gender, arterial
hypertension, repolarization abnormalities on ECG
under resting conditions or after hyperventilation,
and the need to continue drugs such as digitalis or
anti-arrhythmic that potentially induce ST-segment
and T wave changes). Tables 4 and 5 report the main
reasons for test interruption.
2013 ESC guidelines on stable CAD have posed a new
emphasis on the use of non-invasive imaging due to its
significantly higher diagnostic accuracy [22]. However,
the real impact of non-invasive imaging as a gate-keeper
to coronary angiography need to to be tested on out-
comes studies. The reported indications may change
over time due to the evidence accumulating on survival
impact. Exercise ECG remains a first-line in patients
with interpretable ECG due to its simplicity, safety, avail-
ability, low cost, and high negative predictive value. Ap-
propriateness criteria that may shed light on the use of
stress echocardiography are derived from a balance be-
tween hard evidence, expert opinion, clinical experience
and common sense.
Diagnostic accuracy
In a meta-analysis of 55 studies with 3,714 patients, ex-
ercise, dobutamine, dipyridamole, and adenosine echo-
cardiography showed a sensitivity, respectively, of 83, 81,
72, and 79%, and a specificity of 84, 84, 95, and 91%
[23]. In another meta-analysis of 5 studies adopting state
of the art protocols for dipyridamole (fast or atropine-
potentiated) and dobutamine (atropine-potentiated) test,
Table 3 Indications to stress echocardiography
Diagnosis of CAD in patients in whom exercise ECG is contraindicated,
not feasible, uninterpretable, non-diagnostic or gives ambiguous results
Risk stratification in patients with established diagnosis
Pre-operative risk assessment (high-risk non emergent, poor exercise
tolerance)
Evaluation after revascularization (not in the early post-procedure period,
with change in symptoms)
Search for viability in patients with ischemic cardiomyopathy eligible for
revascularization
Coronary artery disease of unclear significance at angiography or
computed tomography
Table 4 Stress echocardiographic diagnostic criteria
Maximal dose or workload
Target heart rate
Echocardiographic Positivity (new or worsening of wall motion
abnormality)
Chest Pain
ECG modification (ST Segment Shift > 2 mm)
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the two stresses had identical sensitivity (84%) and com-
parable specificity (92% vs 87%) [24]. When compared
to standard exercise electrocardiography, stress echocar-
diography has a particularly impressive advantage in
terms of specificity [25]. Compared to nuclear perfusion
imaging, stress echocardiography at least has similar ac-
curacy, with a moderate sensitivity gap that is more than
balanced by a markedly higher specificity [23]. Familiar-
ity with all forms of stress is an index of the quality of
the echo lab. In this way, indications in the individual
patient can be optimised, thereby avoiding the relative
and absolute contraindications of each test. For instance,
a patient with severe hypertension and/or a history of
significant atrial or ventricular arrhythmias can more
reasonably undergo to the dipyridamole stress test
which, unlike dobutamine, has no arrhythmogenic or
hypertensive effect. In contrast, a patient with severe
conduction disturbances or advanced asthmatic disease
should undergo the dobutamine stress test, since adeno-
sine has a negative chronotropic and dromotropic effect,
as well as a documented bronchoconstrictor activity. Pa-
tients either taking xanthine medication or under the ef-
fect of caffeine contained in drinks (tea, coffee, cola)
should undergo the dobutamine test. Both dipyridamole
and dobutamine have overall good tolerance and feasi-
bility. The choice of one test over the other depends
on patient characteristics, local drug cost and the
physician’s preference. It is important for all stress
echocardiography laboratories to become familiar with
all stresses to achieve a flexible and versatile diagnos-
tic approach that enables the best stress to be tailored
to individual patient needs. Antianginal medical ther-
apy (in particular, beta-blocking agents) significantly
affects the diagnostic accuracy of all forms of stress;
therefore, it is recommended, whenever possible, to
withhold medical therapy at the time of testing to
avoid a false-negative result [11, 26].
Prognostic value
The presence (or absence) of inducible wall motion ab-
normalities separates patients with different prognoses.
Information has been obtained from data banks of thou-
sands of patients - also with multicentre design - for ex-
ercise [27–43], dobutamine [44–52], and dipyridamole
[25, 47, 53–57]. A normal stress echocardiogram yields
an annual risk of 0.4–0.9% based on a total of >11000
patients [43], the same as for a normal stress myocardial
perfusion scan (Fig. 1). Thus in patients with suspected
CAD, a normal stress echocardiogram implies excellent
prognosis and coronary angiography can safely be
avoided. The positive and the negative response can be
further stratified with interactions with clinical parame-
ters (diabetes, renal dysfunction, and therapy at the time
of test), resting echo (global LV function), and additive
stress echo parameters (LV cavity dilatation, CFR, and
previous revascularization). While the ischemic or nec-
rotic pattern are associated with markedly increased risk
of death or myocardial infarction, a normal test is pre-
dictive of a generally favorable outcome particularly in
nondiabetic patients [58]. The ischemic response can be
further stratified with additive stress echo parameters,
such as the extent of inducible wall motion abnormal-
ities and the workload/dose [47]. The higher the wall
motion score index and the shorter the ischemia-free
stress time are, the lower is the survival rate [47] (Fig. 2).
As for the prognostic implication of the different
pharmacological stress modalities, a similar prognostic
value has been reported for dobutamine and dipyrid-
amole testing [49]. Antiischemic therapy heavily modu-
lates the prognostic impact of pharmacological stress
echocardiography [59]. Inducible myocardial ischemia in
patients on medical therapy identifies the subset of pa-
tients at highest risk of death. On the opposite end, the
incidence of death in patients with a negative test off
therapy is very low. At intermediate risk are those pa-
tients with a negative test on medical therapy or a posi-
tive test off medical therapy [59] (Fig. 3). The established
prognostic stress echo parameters with their relative
event rate are shown in Tables 6 and 7.
Stress echo in special subsets of patients
Hypertensive patients
In hypertensive patients CFR may be significantly re-
duced independent of the presence of significant CAD.
CFR impairment reduces the diagnostic value of exercise
electrocardiography and nuclear techniques in the
Table 5 Submaximal non diagnostic criteria for test interruption
Intolerable symptoms
Hypertension: Systolic Blood Pressure >220 mmHg; Diastolic Bllood
Pressure > 120 mmHg
Hypotension (Absolute or Relative): Blood Pressure Fall > 30 mmHg
Supraventricular Arrhythmias: Tachycardia; Atrial Fibrillation
Ventricular Arrhythmias: Ventricular Tachycardia; Polymorphous PVCs
Fig. 1 Annual cardiac events associated to a normal stress
echocardiogram and a normal stress myocardial perfusion scan.
From [43]
Sicari and Cortigiani Cardiovascular Ultrasound  (2017) 15:7 Page 4 of 16
hypertensive population, due to high rate of false-
positive responses [10]. In hypertensive patients, stress
echocardiography provides superior diagnostic specificity
than exercise electrocardiography with no differences in
sensitivity [60–62]. Moreover, dipyridamole stress echo-
cardiography is most accurate than perfusion scintig-
raphy to assess coronary artery disease in patients with
exercise electrocardiography positive for ischemia [63].
The prognostic assessment of hypertensive patients is of
primary clinical importance since hypertension is associ-
ated with almost double risk of developing CAD [64].
Stress-induced wall motion abnormality during pharma-
cological testing is a strong multivariable predictor of fu-
ture cardiac events in hypertensive patients with chest
pain of unknown origin [65], including those with LV
hypertrophy [66], and added prognostic information on
top of clinical and exercise electrocardiography [67].
Moreover, the result of test is independently associated
with cardiac death in an unselected cohort of hyperten-
sive patients with known or suspected CAD [68].
However, mortality is predicted by inducible ischemia in
exercise-tested patients and by the presence of any stress
echocardiographic abnormality in those undergoing do-
butamine challenge [69]. Inducible ischemia at inotropic
stress is also associated with unfavourable outcome in
the high-risk population of hypertensive patients unable
to exercise [69]. Exercise-induced change in LV ejection
fraction proved to be a multivariable predictor of mor-
tality incremental to clinical findings, LV mass index,
and resting LV function among hypertensive patients
with LV hypertrophy [70]. Finally, echocardiographic LV
wall motion abnormalities in adults without overt car-
diovascular disease is associated with 2.4 to 3.4 fold
higher risks of cardiovascular morbidity and mortality,
independent of established risk factors [71]. It has been
demonstrated in a large sample of 11.542 patients, that a
normal study with any type of stressor is a marker of
low risk; however in the hypertensive group the risk is
higher [72]. Inducible ischemia at stress echocardiog-
raphy is an independent predictor of hard cardiac
events, and the level of risk is related to the extent of
the inducible abnormality as expressed by peak wall mo-
tion score index [72] (Fig. 4).
Fig. 2 Kaplan-Meier survival curves (considering cardiac death as end point) in patients with pharmacologic stress echocardiography positive for
ischemia stratified on the basis of the extent of ischemia, as expressed by delta wall motion score index (WMSI) set at 0.37 (left panel), and the
dose to induce ischemia (left panel). From [47]
Fig. 3 Kaplan-Meier survival curves (considering total mortality as
end point) in patients stratified according to presence (DET +) or
absence (DET -) of myocardial ischemia at pharmacological stress
echocardiography on and off antianginal medical therapy. From [59]
Table 6 Risk stratification for a positive test
1-year Risk (hard events) Intermediate (1-3% year) High (>10% year)
Dose/workload High Low
Resting EF >50% <40%
Anti-ischaemic therapy Off On
Coronary territory LCx/RCA LAD
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Diabetic patients
Exercise electrocardiography is of limited value in dia-
betic patients because exercise capacity is often impaired
by peripheral vascular disease, neuropathic disease, and
obesity. In addition, test specificity on electrocardio-
graphic criteria is less than ideal due to high prevalence
of hypertension and microvascular disease. Stress echo-
cardiography can play a key role in the optimal identifi-
cation of high risk diabetic patients, also minimizing the
economic and biologic costs of diagnostic screening [1].
The coexistence of epicardial coronary artery stenosis
with microangiopathy can explain the low specificity of
perfusion imaging compared to stress echocardiography
in the detection of CAD in asymptomatic and symptom-
atic diabetic patients [73, 74]. In diabetic patients, stress
echocardiography has shown a higher specificity than
perfusion imaging but suffers from higher rate of false-
positive results, possibly due to the coexistence of car-
diomyopathy in many patients [75]. Risk stratification of
diabetic patients is a major objective for the clinical car-
diologist, given their increased risk for coronary artery
disease [76]. Several studies have addressed the prognos-
tic ability of stratification of non-invasive imaging in pa-
tients with and without diabetes. In particular, in
patients with overt resting ischemic cardiomyopathy, the
presence of myocardial viability recognized by dobuta-
mine stress echocardiography independently predicted
improved outcome following revascularization in nondi-
abetics as well as in diabetic patients following revascu-
larization [77]. Also in unselected patient populations
with proven or suspected CAD, a clear refinement of
prognosis can be obtained with stress echocardiography,
first and foremost on the basis of classical wall motion
abnormalities [58, 78–83], which place the patients in a
high-risk subset for cardiovascular events. The incremental
prognostic information provided by stress echocardiog-
raphy is highest in patients with intermediate-to-high
threshold positive exercise electrocardiography test results
[84]. However, in diabetic patients – differently from nondi-
abetic subjects – a negative test result based solely on wall
motion criteria is associated with less benign outcome [58]
(Fig. 5). In a study on 2,349 diabetic patients investigated
with dobutamine stress echocardiography, the mortality
and cardiovascular morbidity were significantly higher in
subjects with abnormal or ischemic test results [82]. Also,
failure to achieve target heart rate and percentage of ische-
mic segments, an indicator of the extent of inducible ische-
mia, were independent predictors and incremental to
clinical and rest echocardiographic variables for predicting
adverse long-term outcomes [82]. In a more recent study
assessing the long-term follow-up of stress echocardiog-
raphy, dobutamine stress echocardiography provided re-
stricted predictive value of adverse outcome in patients
with diabetes who were unable to perform an adequate ex-
ercise stress test [83]. The Authors also identified a
“warranty” period of the test which provided optimal risk
stratification up to 7 years after initial testing. Repeated do-
butamine stress echocardiography at that time might add
to its prognostic value [83]. In a recent study enrolling a
large sample of 14.000 diabetic and nondiabetic patients,
stress echocardiography showed that a normal study with
any type of stressor is a marker of low risk; however in the
diabetic group the risk is higher [85] (Fig. 5). Inducible is-
chemia at stress echocardiography is an independent pre-
dictor of mortality, and the level of risk is related to the
extent of the inducible abnormality as expressed by peak
wall motion score index. However, the presence of rest wall
motion abnormalities is an independent predictor of mor-
tality in both patient groups [85]. Medical therapy at time
of testing confers a higher risk of mortality in nondiabetics
Table 7 Risk stratification for a negative test
1-year Risk (hard events) Very low (<0.5% year) Low (1-3% year)
Stress Maximal Submaximal
Resting EF >50% <40%
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Fig. 4 Hard event rates for hypertensive and normotensive patients separated on the basis of presence (+) or absence (−) of ischemia at stress
echocardiography, and presence (+) or absence (−) of resting wall motion abnormality (RWMA). From [72]
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but did not appear to impact on outcome in the diabetic
group [85]. The lack of modulation of stress testing by
medical therapy suggest that inducible ischemia is more se-
vere in the diabetic population. Stress myocardial perfusion
imaging can be considered a viable alternative to stress
echocardiography with the limitation of being less available,
more expensive and with potential long-term downstream
detrimental effect due to ionizing radiations [86]. Stress
myocardial perfusion imaging has been shown to have sig-
nificant prognostic power for future cardiac events in the
symptomatic diabetic population. In a large multicenter
study enrolling 4,755 patients (20% diabetic patients) who
underwent exercise of pharmacologic myocardial perfusion
imaging for symptomatic CAD, abnormal stress myocar-
dial perfusion imaging was found to be an independent
predictor of cardiac events in both diabetic and nondia-
betic sample [87]. Moreover, the number of abnormal seg-
ments (fixed or ischemic) was related to worse outcome
[87] and this is consistent with the stress echocardio-
graphic findings showing an ominous outcome for higher
values of wall motion score index.
Women
The diagnostic specificity of exercise electrocardiography
and myocardial perfusion scintigraphy is definitely lower
in women than in men. Reduction of coronary flow re-
serve in syndrome X (mostly affecting female patients),
hormonal influences for exercise testing, and breast
attenuation for nuclear technique are potential explana-
tions. In contrast, echocardiography combined with
exercise or pharmacologic agents provides similar sensi-
tivity but a better specificity as compared to exercise
electrocardiography [88, 89] and perfusion scintigraphy
[90]. In women the prognostic value of stress echocardi-
ography is high, similar to that in men [91]. In patients
with chest pain of unknown origin, a normal test is asso-
ciated with <1% event-rate at 3 years of follow-up, while
an ischemic test is a strong and independent predictor
of future events [92]. Moreover, stress-induced ischemia
adds prognostic information on top of clinical and
exercise electrocardiography data [93] (Fig. 6). In con-
trast to ECG stress test and perfusion imaging, stress
echocardiography is an “equal opportunity” test, with no
difference in diagnostic and prognostic accuracy between
males and females. When exercise electrocardiography
gives positive or ambiguous results, stress echocardiog-
raphy is warranted [94]. The choice of an imaging test in
this setting should take into account the radiologic bur-
den. Recommendations from the European Society of
Cardiology suggest to use non-ionising imaging tech-
niques especially in highly vulnerable subjects such as
younger women [87].
Left bundle branch block
The presence of left bundle branch block makes the
electrocardiogram uninterpretable for ischemia and,
therefore, a stress imaging is necessary. The abnormal
sequence of LV activation determines increased diastolic
extravascular resistance, with lower and slower diastolic
coronary flow, accounting for the stress-induced defect
often observed by perfusion imaging in patients with nor-
mal coronary arteries [95]. In spite of the difficulty posed
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Fig. 5 Mortality for diabetic and nondiabetic patients separated on the basis of presence (+) or absence (−) of ischemia at stress echocardiography, and
presence (+) or absence (−) of resting wall motion abnormality (RWMA). From [85]
Fig. 6 Incremental prognostic value of pharmacological stress
echocardiography to clinical and exercise electrocardiography data,
as determined by the comparison of the global chi-square at each
step. From [93]
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best diagnostic option in patients with left bundle branch
block. It is more specific than perfusion imaging [95], and
its sensitivity is good, albeit reduced in the left anterior de-
scending territory in the presence of a dyskinetic septum
in resting conditions [96]. Moreover, myocardial ischemia
by pharmacologic stress echocardiography has a strong
and independent power in the prediction of future hard
events in left bundle branch block patients, providing a
prognostic contribution that is incremental to that of clin-
ical and resting echo findings in the group without previ-
ous myocardial infarction [97].
Noncardiac vascular surgery
Perioperative ischemia is a frequent event in patients
undergoing major noncardiac vascular or general surgery
and coronary disease is known to be the leading cause of
perioperative mortality and morbidity following vascular
and general surgery [98, 99]. The diagnostic/therapeutic
corollary of these considerations is that CAD – and there-
fore the perioperative risk – in these patients has to be
identified in an effective way preoperatively. This is not
feasible in an accurate way with either clinical scores (such
as Detsky’s or Goldman’s score) or rest echocardiography,
only. The updated ESC guidelines recommend an imaging
stress testing before high-risk surgery in patients with
more than two clinical risk factors and poor functional
capacity (Class I, Evidence C) [98]. Pharmacological stress
echocardiography has been proven to be an effective tool
for risk stratification when compared to perfusion scintig-
raphy [100–112]. Its advantages are due to lower costs
and the lack of ionising radiations and in this particular
setting it is more feasible than exercise stress echo. The
experience with either dipyridamole and dobutamine indi-
cates that these tests have a very high and comparable
negative predictive value (between 90 and 100%) [113]. A
negative test result is associated with a very low incidence
of cardiac events allowing a safe surgical procedure
[113–115]. The positive predictive value is relatively low
(between 25 and 45%): this means that the post-surgical
probability of events is low. Stress echocardiography
shows a comparable diagnostic and prognostic accuracy
when compared to perfusion imaging. The risk stratifica-
tion capability is high for perioperative events and also re-
mains excellent for long-term follow-up [116, 117]. Other
techniques such as CMR and CCTA are available but the
evidence is too scant to be recommended. Moreover, costs
and risks should be weighed in the model of stratification
and high tech imaging techniques do not seem to be ad-
equate for a large scale assessment. Stress testing should
be used in the diagnostic algorithm only when its result
might influence peri-operative management and outcome.
To date, it appears reasonable to perform coronary revas-
cularization before peripheral vascular surgery in the pres-
ence of a markedly positive result of stress
echocardiography in which standard medical therapy ap-
pears insufficient to prevent a peri-operative cardiac event.
A more conservative approach – with watchful cardio-
logical surveillance coupled with pharmacological cardio-
protection with β-blockers – can be adopted in patients
with less severe ischemic responses during stress [99].
Concerns have been raised on the initiation of beta-
blockers before surgery without titration (to avoid
hypotension and bradychardia) and in low risk patients
[118]. Interestingly, clearly inappropriate indications for
preoperative risk stratification before noncardiac surgery
(intermediate risk surgery in patients with good exercise
capacity, and low risk surgery) account for 25% of all in-
appropriate testing in large-volume stress echocardiog-
raphy laboratories [119–122], and therefore this field
provides a key opportunity for quality improvement and
targeted educational programs to achieve measurable im-
provements in results.
Myocardial viability
The stress echo sign of myocardial viability is a stress-
induced improvement of function during low levels of
stress in a region that is abnormal at rest. By far, the
widest experience is available with low-dose dobutamine
stress echocardiography [123–125] the preferred stressor
for assessing myocardial viability. However, it is also pos-
sible to assess the presence of myocardial viability using
low-dose dipyridamole [126–128] or low-level exercise
[129] or enoximone [130, 131].
In patients with dysfunctional but viable myocardium,
regional function can be improved by the inotropic ef-
fect of low-dose (5–10 μg/kg/min.) dobutamine stress
echocardiography [11]. Sensitivity and specificity of low-
dose dobutamine test are, respectively, 86 and 90% for
predicting spontaneous functional recovery after an
acute myocardial infarction (stunning) [123], and 84 and
81% for predicting functional recovery following revas-
cularization in patients with chronic CAD (hibernation)
[124]. Compared to nuclear techniques, dobutamine
stress echocardiography has lower sensitivity, but higher
specificity, with similar overall accuracy regarding recov-
ery of function [124, 125]. In quantitative terms, con-
tractile reserve evidenced by a positive dobutamine
requires at least 50% viable myocytes in a given segment,
whereas scintigraphic methods also identify segments
with less viable myocytes [132]. Minor levels of viability,
characterized by scintigraphic positivity and dobutamine
echocardiography negativity, are often unable to trans-
late into functional recovery. This explains the different
diagnostic performance of the two methods.
Observational studies have indeed suggested that pa-
tients with ischaemic LV dysfunction and a significant
amount of viable myocardium (at least five segments or
a wall motion score index >0.25) [133–142] have lower
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perioperative mortality, greater improvements in regional
and global LV function, fewer heart failure symptoms, and
improved long-term survival after revascularization than
patients with large areas of non-viable myocardium. On
the other hand, viability has no impact on survival in pa-
tients with preserved or just moderately depressed LV
function; in this case, it can rather predict the occurrence
of acute coronary events, representing a substrate for un-
stable ischemic episodes [50].
Viability at dobutamine stress echocardiography pre-
dicts an improved outcome following revascularization
both in diabetic and nondiabetic patients with ischemic
cardiomyopathy [77]. No measurable performance differ-
ence for predicting revascularization benefit between
stress echocardiography and nuclear methods has been
reported [141]. The documentation of viable myocar-
dium at dobutamine test also predicts responders to
resynchronization therapy: patients with contractile re-
serve show a favourable clinical and reverse LV remodel-
ling response to resynchronization therapy [143, 144].
Coronary flow reserve
In recent years the evaluation of CFR by combining
transthoracic Doppler assessment of coronary flow vel-
ocities with vasodilator stress has entered the echo lab
as an effective modality for both diagnostic and prognos-
tic purposes [1]. The use of CFR as a stand-alone diag-
nostic criterion suffers from two main limitations. In
fact, only left anterior descending artery is sampled with
very high success rate. Moreover, CFR cannot distin-
guish between microvascular and macrovascular coron-
ary disease [1]. Therefore it is much more interesting to
assess the additional diagnostic value over conventional
wall motion analysis. CFR of left anterior descending ar-
tery is a strong and independent indicator of mortality,
conferring additional prognostic value over wall motion
analysis in patients with known or suspected CAD [145]
(Fig. 7). A negative result on stress echocardiography
with a normal CFR confers an annual risk of death <1%
[145] (Fig. 7). Moreover, CFR yields useful prognostic in-
formation in several clinical subsets, such as diabetics
with unchanged wall motion during stress [146] (Fig. 8),
hypertensives [147], patients with intermediate coronary
stenosis [148], left bundle branch block [149], and nor-
mal or near normal coronary arteries [147, 149–151]
(Fig. 9). A CFR <2.0 is an additional parameter of ische-
mia severity in the risk stratification of the stress echo-
cardiographic response whereas patients with a negative
test for wall motion criteria and CFR >2.0 during dipyr-
idamole stress echocardiography have a favorable out-
come. Similar results have been obtained when
perfusion imaging was added to wall motion analysis
[152] (Fig. 10). In diabetic patients, a normal CFR is as-
sociated with tighter glycemic control [153] and better
long-term event-free survival both considering unse-
lected patients [146, 154] and patients with angiograph-
ically normal coronary arteries [151] (Fig. 9). Within the
subset of chest pain hypertensive patients with normal
coronary arteries an effective risk stratification has been
obtained according to quartilies of CFR [147] (Fig. 9).
Anti-ischemic medication at the time of testing does not
modulate the prognostic value of CFR, which is per se a
prognostic marker independent of therapy [155] (Fig. 11).
Specialist guidelines endorse an extensive application of
CFR in the stress echo lab, suggesting that “whenever
possible, it is recommended to perform dual imaging
(flow and function) vasodilator stress echo [11].
The shift from qualitative to quantitative reading
The search for a totally operator-independent quantita-
tive tool for stress echocardiography is still on-going.
The state-of-the art diagnosis of ischaemia in stress
echocardiography remains the eyeballing interpretation
of regional wall motion in black and white cine-loops.
Several ultrasound technologies have been proposed
in the last few years in order to overcome the quali-
tative interpretation of stress echocardiography: tissue
characterization, Tissue Doppler imaging, strain rate and
speckle tracking. However, none of these technologies has
a place in the routine clinical practice of stress echo.
EACVI/ASE Guidelines do not recommend its rotine clin-
ical use unless some major limitations and pitfalls are
solved [156]: “While the published research provides the
evidence basis for potential clinical applications of these
techniques in multiple clinical scenarios, the writing group
believes that in the majority of areas, this methodology is
not yet ready for routine clinical use. The consensus is
that: (1) additional testing is needed in multicenter set-
tings to better establish the diagnostic accuracy of the
Fig. 7 Mortality rates in patients with known or suspected coronary
artery disease separated on the basis of presence (+) or absence (−)
of ischemia at stress echocardiography (SE) and coronary flow
reserve (CFR) of left anterior descending artery >2 or ≤2. From [145]
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different parameters and their reproducibility in various
disease states, (2) standardization is needed for what
should be measured and how measurements should be
performed, and (3) standardization among manufacturers
is essential, as clinicians should be able to interpret data
generated by different equipment irrespective of vendor”.
It is conceivable that once the inter-vendor comparability
is solved, speckle tracking would play a relevant role in
determining forms of subtle LV dysfunction and minor
degrees of subendocardial ischemia, otherwise non detect-
able with wall motion analysis. Real-time three
dimensional echocardiography has also proven to be ac-
curate and reproducible, but it remains time consuming
and frame rates are too low for stress echocardiography
[1]. The EACVI/ASE consensus document states that 3D
stress transthoracic echocardiography holds promise for
incorporation into clinical practice in the future [157]. Its
advantages are: 1. Better visualization of the LV apex,
which is frequently foreshortened on standard 2D apical
images; 2. Rapid acquisition of peak stress images before
the heart declines in recovery; and 3. Evaluation of mul-
tiple segments from different planes from a single data set.
Fig. 8 Hard event rates in diabetic and nondiabetic patients with stress echo negative for ischemia separated on the basis of coronary flow
reserve (CFR) of left anterior descending artery >2 or ≤2. From [146]
Fig. 9 Hard event rates in unselected patients (left upper panel), hypertensives patients (right upper panel), diabetic patients (left lower panel), and
patients with left bundle branch block (LBBB) (right lower panel) with normal or near normal coronary arteries separated on the basis of coronary
flow reserve (CFR) values. From [147, 149–151]
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Disadvantages include lower spatial resolution and lower
frame rates [157].
Myocardial contrast echocardiography (MCE) has
undergone rapid development in the past 5 years. With
the advent of newer-generation microbubbles, intraven-
ous agents can now be used to both improve endocardial
border delineation and, detect myocardial perfusion.
Along with the development of microbubbles which
consistently opacify the left heart from a venous injec-
tion, newer imaging modalities have evolved which per-
mit the detection of myocardial perfusion abnormalities
in real time, at frame rates which are greater than 25Hz.
In order to accurately detect wall motion abnormalities
during stress echocardiography, a clear definition of
endocardial borders is of particularly importance. The
approved indication for the use of contrast echocardiog-
raphy currently lies in improving endocardial border de-
lineation in patients in whom adequate imaging is
difficult or suboptimal [158].
Safety of pharmacologic stress echocardiography
Stress echocardiography is a safe technique but minor,
limiting, side effects may preclude the achievement of
maximal testing. Safety profile of stress echocardiog-
raphy depends on the stressor used. Exercise is the safest
stressor as shown in large samples with the long – lasting
experience of ECG stress test [159]. Stress echo registries
collecting data on thousands of patients [160–163] have
shown that exercise is the safest test. Death has an
incidence rate of 1 in 10,000 tests. Major life-threatening
effects (myocardial infarction, ventricular fibrillation, sus-
tained ventricular tachycardia, stroke) occur in about 1 in
6000 patients with exercise in the international stress
echocardiography registry – fivefold less than with dipyr-
idamole echocardiography and tenfold less than with do-
butamine echocardiography. Exercise, whenever feasible,
should be the preferred stressor due to its safety profile.
Exercise is safer than pharmacological stress echocardiog-
raphy and dipyridamole is safer than dobutamine . Not all
stress tests carry the same risk of major adverse reactions
and the choice of one test over the other should take into
account the safety profile.
Conclusions
Stress echocardiography is an established technique for
the assessment of known or suspected CAD. It is recom-
mended in all major cardiology guidelines in several
clinical settings. However, its status of established tech-
nology, should prompt its clinical use as the preferred
non-invasive imaging technique due to its low cost, wide
availability and lack of radiation exposure. Though these
unique features, an utilization gap remains with nuclear
techniques percevied as more objective in the face of a
comparable diagnostic and prognostic accuracy. The flex-
ible use of stressors (exercise, inotropic and vasodilating)
maximazes the feasibility, avoids specific contra-indications
and allows tailoring the exam on each individual patient. A
paradigm shift will occur when from a highly expertise
qualitative reading stress echocardiography will move to a
quantitative approach that would make it easier also for
less skilled readers. Technological premises are there at
hand but they have not reached a fullblown status to be
used on a routine clinical basis. Society recommendantions
and guidelines are mostly based on consensus and level of
evidence C. The gap of knowledge should be filled with
prospective large scale studies to support evidence-based
treatment strategies. Eugenio Picano and Patricia Pellikka,
two pioneers of the technique invite the scientific commu-
nity to design “prospective large scale and (when possible)
randomised (medical vs. interventional treatment) out-
come studies to support more evidence-based rather than
consensus-based strategies, based on stress echo results, in
CAD and non-CAD patients” [164].
Fig. 10 Kaplan-Meier curves based on the combination of presence or
absence of wall motion (WM) abnormalities and myocardial perfusion
(MP) abnormalities. From [152]
Fig. 11 Kaplan-Meier survival curves (considering hard events as end
point) in patients stratified on the basis of coronary flow reserve (CFR)
of left anterior descending artery >2 or ≤2 on and off antianginal
medical therapy. From [155]
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